Press releases & announcements
13 September, 2017
RhoVac AB (“RhoVac”) will, as a natural step in the company’s international communication, participate in Nordic Life Science Days in Malmö, Sweden in September 2017. The company will also present... [Read more]
21 August, 2017
RhoVac AB (“RhoVac”) announced today, August 21 2017, that the company has signed an agreement with Lund University on research collaboration on cancer stem cells and on the expression of... [Read more]
17 August, 2017
RhoVac AB (“RhoVac”) announced that in January 2017, the company received the respective medicines agency and ethical committee’s approval for the start of the Phase I/II study. The study started... [Read more]
RhoVac in Brief
RhoVac undertakes research and development of therapeutic cancer vaccines. The primary candidate, RV001, targets RhoC which is overexpressed in cancer cells with metastatic potential.
Because most cancers form metastases, RV001 can potentially be used to treat a broad range of cancers. RhoVac's concept focuses on eliminating metastatic cancer cells that may escape treatment of the parent tumour via other methods. Because RhoC is not expressed in the parent tumour, the company goal is to use the developed product in combination with another therapy -- specifically, treatment of the parent tumour by e.g. surgery, radiotherapy or chemotherapy together with treatment with the therapeutic cancer vaccine to combat metastasis.